ArticleIntensive care medicine2023
Renal outcomes following intravenous contrast administration in patients with acute kidney injury: a multi-site retrospective propensity-adjusted analysis.
Article in Intensive care medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 42 citations in OpenAlex.
- Feasibility pilot study of the use of ultra-low dose iodinated contrast agent for endovascular procedures in patients with chronic limb-threatening ischemia and renal impairment: the ULTRA-LOW study.CVIR endovascular · 2026Article
- Chrysophanol ameliorates ferroptosis in acute kidney injury by promoting SIRT3-mediated NRF2 deacetylation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Computed Tomography Yield and Predictors of Pulmonary Embolism in Mechanically Ventilated Patients-A Retrospective Study.Acta anaesthesiologica Scandinavica · 2026Article
- Contrast Media in Hospitalized Patients with Acute Kidney Injury: Renal and Clinical Outcomes.American journal of nephrology · 2026Article
- Time To Inject Some Contrast into the Nephrotoxicity Debate.Kidney360 · 2026Article
- Article
- Incidence and risk factors of contrast-associated acute kidney injury in patients hospitalised after contrast-enhanced computed tomography in the emergency department.International journal of emergency medicine · 2025Article
- Management of acute myocardial infarction in chronic kidney disease in Germany: an observational study.BMC nephrology · 2025Observational
- Lipin3 deficiency aggravates cisplatin induced acute kidney injury via activating Sirt1-p21-Caspase 3-GSDME pyroptosis pathway.International journal of biological sciences · 2025Article
- The Protective Role of Intermedin in Contrast-Induced Acute Kidney Injury: Enhancing Peritubular Capillary Endothelial Cell Adhesion and Integrity Through the cAMP/Rac1 Pathway.International journal of molecular sciences · 2024Article
- No trauma-related diagnosis in emergency trauma room whole-body computer tomography of patients with inconspicuous primary survey.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2024Article
- High and intermediate risk pulmonary embolism in the ICU.Intensive care medicine · 2024Review
- Failing kidneys: renal replacement therapies in the ICU.Trauma surgery & acute care open · 2024Review
- Post-infarction Left Ventricular Free Wall Rupture Diagnosed by Contrast-Enhanced Computed Tomography: A Case Report.Cureus · 2024Article
- Clinical usefulness of urinary biomarkers for early prediction of acute kidney injury in patients undergoing transaortic valve implantation.Scientific reports · 2023Article
- Radiomic analysis of abdominal organs during sepsis of digestive origin in a French intensive care unit.Acute and critical care · 2023Article
- Kidney Injury in Critically Ill Patients with COVID-19 - From Pathophysiological Mechanisms to a Personalized Therapeutic Model.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2023Review
Corrections and comments
- Comment on
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
purposeEvidence of an association between intravenous contrast media (CM) and persistent renal dysfunction is lacking for patients with pre-existing acute kidney injury (AKI). This study was designed to determine the association between intravenous CM administration and persistent AKI in patients with pre-existing AKI.
methodsA retrospective propensity-weighted and entropy-balanced observational cohort analysis of consecutive hospitalized patients ≥ 18 years old meeting Kidney Disease Improving Global Outcomes (KDIGO) creatinine-based criteria for AKI at time of arrival to one of three emergency departments between 7/1/2017 and 6/30/2021 who did or did not receive intravenous CM. Outcomes included persistent AKI at hospital discharge and initiation of dialysis within 180 days of index encounter.
resultsOur analysis included 14,449 patient encounters, with 12.8% admitted to the intensive care unit (ICU). CM was administered in 18.4% of all encounters. AKI resolved prior to hospital discharge for 69.1%. No association between intravenous CM administration and persistent AKI was observed after unadjusted multivariable logistic regression modeling (OR 1; 95% CI 0.89-1.11), propensity weighting (OR 0.93; 95% CI 0.83-1.05), and entropy balancing (OR 0.94; 95% CI 0.83-1.05). Sub-group analysis in those admitted to the ICU yielded similar results. Initiation of dialysis within 180 days was observed in 5.4% of the cohort. An association between CM administration and increased risk of dialysis within 180 days was not observed.
conclusionAmong patients with pre-existing AKI, contrast administration was not associated with either persistent AKI at hospital discharge or initiation of dialysis within 180 days. Current consensus recommendations for use of intravenous CM in patients with stable renal disease may also be applied to patients with pre-existing AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.